Anti human ovarian cancer-anti CD3 bispecific antibody

Details Anti human ovarian cancer-anti CD3 bispecific antibody Anti human ovarian cancer-anti CD3 bispecific antibody

2007-08-28

2007-08-28

Foley, Shanon (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387700

Reexamination Certificate

active

10478345

ABSTRACT:
The present invention provides an anti-ovarian cancer bispecific antibody. Said antibody includes two polypeptide domains connected by a polypeptide linker, one is anti-ovarian cancer antibody, or its Fab fragment, single complementarity determining region (CDR) antibody or single chain Fv (scFv) and the other is anti-CD3 antibody, or its Fab fragment, single CDR antibody or scFv. The present invention also provides DNA sequences encoding said antibody, an expression vector containing said DNA sequence, and a host cell containing said expression vector.

REFERENCES:
patent: 6027725 (2000-02-01), Whitlow et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 6146628 (2000-11-01), Uckun et al.
patent: 0505908 (1992-09-01), None
patent: 93/16185 (1993-08-01), None
patent: 03/04648 (2003-01-01), None
Kriangkum et al (Hybridoma, 2000, 19:33-41).
Kriangum et al (Hybridoma, Feb. 2000, 19:33-41).
Marken et al (J of Biological Chemistry, 1994, 269, 73977401).

Affiliated with

Also associated with

Rating

Anti human ovarian cancer-anti CD3 bispecific antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti human ovarian cancer-anti CD3 bispecific antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti human ovarian cancer-anti CD3 bispecific antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3876632